整合常染色体显性多囊肾病预测工具进行风险预后评估
该回顾性多中心队列研究纳入468例常染色体显性多囊肾病(ADPKD)患者,结合梅奥影像分类(MIC)与PROPKD评分等工具构建联合模型。结果显示MIC与PROPKD一致性较低,联合使用可提高识别快速进展者(尤其中等风险患者)的能力。
要点
- MIC与PROPKD评分一致性低,联合使用可改善风险分层。
- PKD1基因型、MIC 1E类、早发高血压和早发泌尿事件与快速进展相关。
- MIC特异性较好(77%),PROPKD敏感性更高(59%)。
核心结论
- 联合使用MIC和PROPKD评分能更准确识别快速进展者,尤其在中等风险患者中改善分层。
研究设计与样本
- 回顾性多中心队列研究,纳入468例确诊ADPKD患者,分析临床、影像和遗传数据。
主要发现
- 多变量分析中,PKD1基因型(P < 0.001)、MIC 1E类(P < 0.001)、早发高血压(P < 0.001)和早发泌尿事件(P = 0.003)与快速进展相关性最强。
- MIC特异性为77%,PROPKD敏感性为59%。
- 在某一评分中等风险的患者中,联合另一评分可更准确分层。
关键数值与推荐
- 快速进展定义为2年内eGFR斜率≥3 ml/min per 1.73 m2 per year,或MIC 1D–1E,或PROPKD评分≥7分。
- 主要终点为进展至CKD G4–G5期、eGFR纵向变化及高血压或泌尿事件等临床变量。
临床怎么用
- 对ADPKD患者可联合使用MIC和PROPKD评分进行风险分层,以辅助判断特定治疗指征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: The Mayo clinic imaging classification and the predicting renal outcome in polycystic kidney disease score are used to assess the risk of progression to kidney failure in autosomal dominant polycystic kidney disease. Mayo imaging classification and predicting renal outcome in polycystic kidney disease show little concordance; combined use increased the ability to identify rapid progression especially among intermediate risk patients. Accurate risk prediction is key for determining indication for specific treatment. BACKGROUND: Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. Specific treatment is indicated on observed or predicted rapid progression. For the latter, risk stratification tools have been developed independently based on either total kidney volume or genotyping as well as clinical variables. This study aimed to improve risk prediction by combining both imaging and clinical-genetic scores. METHODS: We conducted a retrospective multicenter cohort study of 468 patients diagnosed with autosomal dominant polycystic kidney disease. Clinical, imaging, and genetic data were analyzed for risk prediction. We defined rapid disease progression as an eGFR slope ≥3 ml/min per 1.73 m2 per year over 2 years, Mayo imaging classification (MIC) 1D–1E, or a predicting renal outcome in polycystic kidney disease (PROPKD) score of ≥7 points. Using MIC, PROPKD, and rare exome variant ensemble learner scores, several combined models were designed to develop a new classification with improved risk stratification. Primary endpoints were the development of advanced CKD stages G4–G5, longitudinal changes in eGFR, and clinical variables such as hypertension or urological events. Statistically, logistic regression, survival, receiver operating characteristic analyses, linear mixed models, and Cox proportional hazards models were used. RESULTS: PKD1-genotype (P < 0.001), MIC class 1E (P < 0.001), early-onset hypertension (P < 0.001), and early-onset urological events (P = 0.003) correlated best with rapid progression in multivariable analysis. While the MIC showed satisfactory specificity (77%), the PROPKD was more sensitive (59%). Among individuals with an intermediate risk in one of the scores, integration of the other score (combined scoring) allowed for more accurate stratification. CONCLUSIONS: The combined use of both risk scores was associated with higher ability to identify rapid progressors and resulted in a better stratification, notably among intermediate risk patients.
引用
- Wolff CA, Aiello V, Elhassan EAE, et al. Integrated Use of Autosomal Dominant Polycystic Kidney Disease Prediction Tools for Risk Prognostication. Clin J Am Soc Nephrol. 2024. PMID: 39705090. doi:10.2215/CJN.0000000625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。